-
1
-
-
70849122251
-
Triple-negative breast cancer-current status and future directions
-
19901010 10.1093/annonc/mdp492 1:STN:280:DC%2BD1MjnsVGjug%3D%3D
-
O Gluz C Liedtke N Gottschalk L Pusztai U Nitz N Harbeck 2009 Triple-negative breast cancer-current status and future directions Ann Oncol 20 1913 1927 19901010 10.1093/annonc/mdp492 1:STN:280:DC%2BD1MjnsVGjug%3D%3D
-
(2009)
Ann Oncol
, vol.20
, pp. 1913-1927
-
-
Gluz, O.1
Liedtke, C.2
Gottschalk, N.3
Pusztai, L.4
Nitz, U.5
Harbeck, N.6
-
2
-
-
0032547564
-
Polychemotherapy for early breast cancer: An overview of the randomised trials
-
DOI 10.1016/S0140-6736(98)03301-7
-
Early Breast Cancer Trialists' Collaborative Group. (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 930 942 10.1016/S0140-6736(98)03301-7 (Pubitemid 28427277)
-
(1998)
Lancet
, vol.352
, Issue.9132
, pp. 930-942
-
-
Clarke, M.1
Collins, R.2
Davies, C.3
Godwin, J.4
Gray, R.5
Peto, R.6
-
3
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
-
(2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
-
(2005)
Lancet
, vol.365
, pp. 1687-1717
-
-
-
4
-
-
0038688702
-
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: A study by the GEICAM group
-
DOI 10.1093/annonc/mdg260
-
M Martin A Villar A Sole-Calvo R Gonzalez B Massuti J Lizon C Camps A Carrato A Casado MT Candel J Albanell J Aranda B Munarriz J Campbell E Diaz-Rubio 2003 Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group Ann Oncol 14 833 842 12796019 10.1093/annonc/mdg260 1:STN:280: DC%2BD3s3mvFGnsw%3D%3D (Pubitemid 36827198)
-
(2003)
Annals of Oncology
, vol.14
, Issue.6
, pp. 833-842
-
-
Martin, M.1
Villar, A.2
Sole-Calvo, A.3
Gonzalez, R.4
Massuti, B.5
Lizon, J.6
Camps, C.7
Carrato, A.8
Casado, A.9
Candel, M.T.10
Albanell, J.11
Aranda, J.12
Munarriz, B.13
Campbell, J.14
Diaz-Rubio, E.15
-
5
-
-
24044542973
-
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: A pooled analysis of three randomised trials
-
DOI 10.1016/S1470-2045(05)70255-2, PII S1470204505702552
-
M Di Maio C Gridelli C Gallo F Shepherd FV Piantedosi S Cigolari L Manzione A Illiano S Barbera SF Robbiati L Frontini E Piazza GP Ianniello E Veltri F Castiglione F Rosetti V Gebbia L Seymour P Chiodini F Perrone 2005 Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials Lancet Oncol 6 669 677 16129367 10.1016/S1470-2045(05)70255-2 1:CAS:528: DC%2BD2MXpslynsr0%3D (Pubitemid 41222757)
-
(2005)
Lancet Oncology
, vol.6
, Issue.9
, pp. 669-677
-
-
Di Maio, M.1
Gridelli, C.2
Gallo, C.3
Shepherd, F.4
Piantedosi, F.V.5
Cigolari, S.6
Manzione, L.7
Illiano, A.8
Barbera, S.9
Robbiati, S.F.10
Frontini, L.11
Piazza, E.12
Ianniello, G.P.13
Veltri, E.14
Castiglione, F.15
Rosetti, F.16
Gebbia, V.17
Seymour, L.18
Chiodini, P.19
Perrone, F.20
more..
-
6
-
-
34347334619
-
Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma
-
DOI 10.1038/sj.bjc.6603831, PII 6603831
-
T Yamanaka S Matsumoto S Teramukai R Ishiwata Y Nagai M Fukushima 2007 Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma Br J Cancer 97 37 42 17551497 10.1038/sj.bjc.6603831 1:CAS:528:DC%2BD2sXmvV2ms7g%3D (Pubitemid 47012089)
-
(2007)
British Journal of Cancer
, vol.97
, Issue.1
, pp. 37-42
-
-
Yamanaka, T.1
Matsumoto, S.2
Teramukai, S.3
Ishiwata, R.4
Nagai, Y.5
Fukushima, M.6
-
7
-
-
66949165187
-
Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
-
19217278 10.1016/j.ejca.2009.01.019 1:CAS:528:DC%2BD1MXnsV2lu70%3D
-
K Shitara K Matsuo D Takahari T Yokota Y Inaba H Yamaura Y Sato M Najima T Ura K Muro 2009 Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX Eur J Cancer 45 1757 1763 19217278 10.1016/j.ejca.2009.01.019 1:CAS:528:DC%2BD1MXnsV2lu70%3D
-
(2009)
Eur J Cancer
, vol.45
, pp. 1757-1763
-
-
Shitara, K.1
Matsuo, K.2
Takahari, D.3
Yokota, T.4
Inaba, Y.5
Yamaura, H.6
Sato, Y.7
Najima, M.8
Ura, T.9
Muro, K.10
-
8
-
-
0031031616
-
Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer
-
T Saarto C Blomqvist P Rissanen A Auvinen I Elomaa 1997 Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer Br J Cancer 75 301 305 9010042 10.1038/bjc.1997.49 1:CAS:528: DyaK2sXhtFGksLY%3D (Pubitemid 27019578)
-
(1997)
British Journal of Cancer
, vol.75
, Issue.2
, pp. 301-305
-
-
Saarto, T.1
Blomqvist, C.2
Rissanen, P.3
Auvinen, A.4
Elomaa, I.5
-
9
-
-
0032774739
-
Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
-
DOI 10.1038/sj.bjc.6690594
-
P Poikonen T Saarto J Lundin H Joensuu C Blomqvist 1999 Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF Br J Cancer 80 1763 1766 10468293 10.1038/sj.bjc.6690594 1:CAS:528:DyaK1MXlvFGntLw%3D (Pubitemid 29389629)
-
(1999)
British Journal of Cancer
, vol.80
, Issue.11
, pp. 1763-1766
-
-
Poikonen, P.1
Saarto, T.2
Lundin, J.3
Joensuu, H.4
Blomqvist, C.5
-
10
-
-
0348013443
-
Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer
-
DOI 10.1038/sj.bjc.6601366
-
DA Cameron C Massie G Kerr RC Leonard 2003 Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer Br J Cancer 89 1837 1842 14612889 10.1038/sj.bjc.6601366 1:CAS:528:DC%2BD3sXovVers7o%3D (Pubitemid 37533256)
-
(2003)
British Journal of Cancer
, vol.89
, Issue.10
, pp. 1837-1842
-
-
Cameron, D.A.1
Massie, C.2
Kerr, G.3
Leonard, R.C.F.4
-
11
-
-
77951242562
-
Prognostic significance of neutropenia on day one of anthracycline-based neoadjuvant chemotherapy in operable breast cancer
-
Ishitobi M, Komoike Y, Motomura K, Koyama H, and Inaji H Prognostic significance of neutropenia on day one of anthracycline-based neoadjuvant chemotherapy in operable breast cancer. Oncology 78:213-219
-
Oncology
, vol.78
, pp. 213-219
-
-
Ishitobi, M.1
Komoike, Y.2
Motomura, K.3
Koyama, H.4
Inaji, H.5
-
12
-
-
0024469561
-
Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas
-
V Le Doussal M Tubiana-Hulin S Friedman K Hacene F Spyratos M Brunet 1989 Prognostic value of histologic grade nuclear components of Scarff-Bloom- Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas Cancer 64 1914 1921 2551477 10.1002/1097-0142(19891101)64:9<1914::AID-CNCR2820640926>3.0.CO;2-G 1:STN:280:DyaK3c%2Fgt1Oqtg%3D%3D (Pubitemid 19267813)
-
(1989)
Cancer
, vol.64
, Issue.9
, pp. 1914-1921
-
-
Le Doussal, V.1
Tubiana-Hulin, M.2
Friedman, S.3
Hacene, K.4
Spyratos, F.5
Brunet, M.6
-
13
-
-
21144435932
-
Adjuvant docetaxel for node-positive breast cancer
-
DOI 10.1056/NEJMoa043681
-
M Martin T Pienkowski J Mackey M Pawlicki JP Guastalla C Weaver E Tomiak T Al-Tweigeri L Chap E Juhos R Guevin A Howell T Fornander J Hainsworth R Coleman J Vinholes M Modiano T Pinter SC Tang B Colwell C Prady L Provencher D Walde A Rodriguez-Lescure J Hugh C Loret M Rupin S Blitz P Jacobs M Murawsky A Riva C Vogel 2005 Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2302 2313 15930421 10.1056/NEJMoa043681 1:CAS:528:DC%2BD2MXksl2lt7c%3D (Pubitemid 40740554)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.22
, pp. 2302-2313
-
-
Martin, M.1
Pienkowski, T.2
Mackey, J.3
Pawlicki, M.4
Guastalla, J.-P.5
Weaver, C.6
Tomiak, E.7
Al-Tweigeri, T.8
Chap, L.9
Juhos, E.10
Guevin, R.11
Howell, A.12
Fornander, T.13
Hainsworth, J.14
Coleman, R.15
Vinholes, J.16
Modiano, M.17
Pinter, T.18
Tang, S.C.19
Colwell, B.20
Prady, C.21
Provencher, L.22
Walde, D.23
Rodriguez-Lescure, A.24
Hugh, J.25
Loret, C.26
Rupin, M.27
Blitz, S.28
Jacobs, P.29
Murawsky, M.30
Riva, A.31
Vogel, C.32
more..
-
14
-
-
27744441618
-
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer
-
DOI 10.1016/S1470-2045(05)70424-1, PII S1470204505704241
-
M Trudeau F Charbonneau K Gelmon K Laing J Latreille J Mackey D McLeod K Pritchard L Provencher S Verma 2005 Selection of adjuvant chemotherapy for treatment of node-positive breast cancer Lancet Oncol 6 886 898 16257797 10.1016/S1470-2045(05)70424-1 1:CAS:528:DC%2BD2MXhtFOmsb%2FI (Pubitemid 41614801)
-
(2005)
Lancet Oncology
, vol.6
, Issue.11
, pp. 886-898
-
-
Trudeau, M.1
Charbonneau, F.2
Gelmon, K.3
Laing, K.4
Latreille, J.5
Mackey, J.6
McLeod, D.7
Pritchard, K.8
Provencher, L.9
Verma, S.10
-
15
-
-
53949091207
-
Neutropenia occurrence and predictors of reduced chemotherapy delivery: Results from the INC-EU prospective observational European neutropenia study
-
18351398 10.1007/s00520-008-0430-4
-
R Pettengell M Schwenkglenks R Leonard A Bosly R Paridaens M Constenla TD Szucs C Jackisch 2008 Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study Support Care Cancer 16 1299 1309 18351398 10.1007/s00520-008-0430-4
-
(2008)
Support Care Cancer
, vol.16
, pp. 1299-1309
-
-
Pettengell, R.1
Schwenkglenks, M.2
Leonard, R.3
Bosly, A.4
Paridaens, R.5
Constenla, M.6
Szucs, T.D.7
Jackisch, C.8
-
16
-
-
0347985317
-
Chemotherapy-Induced Neutropenia: Risks, Consequences, and New Directions for Its Management
-
DOI 10.1002/cncr.11882
-
J Crawford DC Dale GH Lyman 2004 Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management Cancer 100 228 237 14716755 10.1002/cncr.11882 (Pubitemid 38063629)
-
(2004)
Cancer
, vol.100
, Issue.2
, pp. 228-237
-
-
Crawford, J.1
Dale, D.C.2
Lyman, G.H.3
-
17
-
-
0032788580
-
The leucocyte nadir, a predictor of chemotherapy efficacy?
-
DOI 10.1038/sj.bjc.6690583
-
S Kvinnsland 1999 The leucocyte nadir, a predictor of chemotherapy efficacy? Br J Cancer 80 1681 10468282 10.1038/sj.bjc.6690583 1:STN:280:DyaK1Mzps1emug%3D%3D (Pubitemid 29389618)
-
(1999)
British Journal of Cancer
, vol.80
, Issue.11
, pp. 1681
-
-
Kvinnsland, S.1
-
18
-
-
0035875895
-
Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma
-
DOI 10.1002/1097-0142(20010615)91:12<2246::AID-CNCR1255>3.0.CO;2-4
-
C Mayers T Panzarella IF Tannock 2001 Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma Cancer 91 2246 2257 11413512 10.1002/1097-0142(20010615)91:12<2246::AID-CNCR1255>3.0.CO;2-4 1:STN:280:DC%2BD3MzkvFGksw%3D%3D (Pubitemid 32552809)
-
(2001)
Cancer
, vol.91
, Issue.12
, pp. 2246-2257
-
-
Mayers, C.1
Panzarella, T.2
Tannock, I.F.3
-
19
-
-
33749054885
-
Moderate Neutropenia with S-1 Plus Low-dose Cisplatin May Predict a More Favourable Prognosis in Advanced Gastric Cancer
-
DOI 10.1016/j.clon.2006.07.007, PII S0936655506002585
-
B Nakata A Tsuji Y Mitachi S Yamamitsu K Hirata T Takeuchi T Shirasaka K Hirakawa 2006 Moderate neutropenia with S-1 plus low-dose cisplatin may predict a more favourable prognosis in advanced gastric cancer Clin Oncol (R Coll Radiol) 18 678 683 10.1016/j.clon.2006.07.007 1:STN:280:DC%2BD28nmsFaqug%3D%3D (Pubitemid 44464046)
-
(2006)
Clinical Oncology
, vol.18
, Issue.9
, pp. 678-683
-
-
Nakata, B.1
Tsuji, A.2
Mitachi, Y.3
Yamamitsu, S.4
Hirata, K.5
Takeuchi, T.6
Shirasaka, T.7
Hirakawa, K.8
-
20
-
-
0027282915
-
Premenopausal patients with node-positive resectable breast cancer: Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles
-
P Fumoleau Y Devaux ML Vo Van P Kerbrat P Fargeot S Schraub J Mihura M Namer M Mercier 1993 Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 × 6 cycles vs FEC 50 × 3 cycles vs FEC 75 × 3 cycles. The French Adjuvant Study Group Drugs 45 Suppl 2 38 45 7693420 10.2165/00003495-199300452-00007 (Pubitemid 23262207)
-
(1993)
Drugs
, vol.46
, Issue.SUPPL. 2
, pp. 38-45
-
-
Fumoleau, P.1
Devaux, Y.2
Vo Van, M.L.3
Kerbrat, P.4
Fargeot, P.5
Schraub, S.6
Mihura, J.7
Namer, M.8
Mercier, M.9
Van Oosterom, A.10
-
21
-
-
0028274962
-
Dose and dose intensity of adjuvant chemotherapy for stage II, node- positive breast carcinoma
-
DOI 10.1056/NEJM199405053301801
-
WC Wood DR Budman AH Korzun MR Cooper J Younger RD Hart A Moore JA Ellerton L Norton CR Ferree, et al. 1994 Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma N Engl J Med 330 1253 1259 8080512 10.1056/NEJM199405053301801 1:STN:280:DyaK2c7psFensA%3D%3D (Pubitemid 24129957)
-
(1994)
New England Journal of Medicine
, vol.330
, Issue.18
, pp. 1253-1259
-
-
Wood, W.C.1
Budman, D.R.2
Korzun, A.H.3
Cooper, M.R.4
Younger, J.5
Hart, R.D.6
Moore, A.7
Ellerton, J.A.8
Norton, L.9
Ferree, C.R.10
Ballow, A.C.11
Frei III, E.12
Henderson, I.C.13
-
22
-
-
0030913595
-
Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B- 22
-
B Fisher S Anderson DL Wickerham A DeCillis N Dimitrov E Mamounas N Wolmark R Pugh JN Atkins FJ Meyers N Abramson J Wolter RS Bornstein L Levy EH Romond V Caggiano M Grimaldi P Jochimsen P Deckers 1997 Increased intensification and total dose of cyclophosphamide in a doxorubicin- cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22 J Clin Oncol 15 1858 1869 9164196 1:CAS:528:DyaK2sXjsVClsbc%3D (Pubitemid 27209515)
-
(1997)
Journal of Clinical Oncology
, vol.15
, Issue.5
, pp. 1858-1869
-
-
Fisher, B.1
Anderson, S.2
Wickerham, D.L.3
DeCillis, A.4
Dimitrov, N.5
Mamounas, E.6
Wolmark, N.7
Pugh, R.8
Atkins, J.N.9
Meyers, F.J.10
Abramson, N.11
Wolter, J.12
Bornstein, R.S.13
Levy, L.14
Romond, E.H.15
Caggiano, V.16
Grimaldi, M.17
Jochimsen, P.18
Deckers, P.19
-
23
-
-
0034699950
-
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study
-
11052580 10.1016/S0140-6736(00)02841-5 1:CAS:528:DC%2BD3cXot1WqtL4%3D
-
J Bergh T Wiklund B Erikstein E Lidbrink H Lindman P Malmstrom P Kellokumpu-Lehtinen NO Bengtsson G Soderlund G Anker E Wist S Ottosson E Salminen P Ljungman H Holte J Nilsson C Blomqvist N Wilking 2000 Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study Lancet 356 1384 1391 11052580 10.1016/S0140-6736(00)02841-5 1:CAS:528:DC%2BD3cXot1WqtL4%3D
-
(2000)
Lancet
, vol.356
, pp. 1384-1391
-
-
Bergh, J.1
Wiklund, T.2
Erikstein, B.3
Lidbrink, E.4
Lindman, H.5
Malmstrom, P.6
Kellokumpu-Lehtinen, P.7
Bengtsson, N.O.8
Soderlund, G.9
Anker, G.10
Wist, E.11
Ottosson, S.12
Salminen, E.13
Ljungman, P.14
Holte, H.15
Nilsson, J.16
Blomqvist, C.17
Wilking, N.18
-
24
-
-
0029743058
-
Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative
-
H Gurney 1996 Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative J Clin Oncol 14 2590 2611 8823340 1:CAS:528:DyaK28XlvVGisLg%3D (Pubitemid 26300128)
-
(1996)
Journal of Clinical Oncology
, vol.14
, Issue.9
, pp. 2590-2611
-
-
Gurney, H.1
-
25
-
-
0037156937
-
How to calculate the dose of chemotherapy
-
11953888 10.1038/sj.bjc.6600139 1:CAS:528:DC%2BD38XksVSmtLs%3D
-
H Gurney 2002 How to calculate the dose of chemotherapy Br J Cancer 86 1297 1302 11953888 10.1038/sj.bjc.6600139 1:CAS:528:DC%2BD38XksVSmtLs%3D
-
(2002)
Br J Cancer
, vol.86
, pp. 1297-1302
-
-
Gurney, H.1
-
26
-
-
0031804616
-
Body-surface area as a basis for dosing of anticancer agents: Science, myth, or habit?
-
MJ Ratain 1998 Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 16 2297 2298 9667242 1:STN:280:DyaK1czivFyitA%3D%3D (Pubitemid 28309019)
-
(1998)
Journal of Clinical Oncology
, vol.16
, Issue.7
, pp. 2297-2298
-
-
Ratain, M.J.1
-
27
-
-
0037156942
-
Getting the right dose in cancer chemotherapy-time to stop using surface area?
-
11953873 10.1038/sj.bjc.6600226 1:STN:280:DC%2BD383hs1Kmtw%3D%3D
-
DR Newell 2002 Getting the right dose in cancer chemotherapy-time to stop using surface area? Br J Cancer 86 1207 1208 11953873 10.1038/sj.bjc.6600226 1:STN:280:DC%2BD383hs1Kmtw%3D%3D
-
(2002)
Br J Cancer
, vol.86
, pp. 1207-1208
-
-
Newell, D.R.1
-
28
-
-
0035449571
-
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure
-
FE de Jongh J Verweij WJ Loos R de Wit MJ de Jonge AS Planting K Nooter G Stoter A Sparreboom 2001 Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure J Clin Oncol 19 3733 3739 11533095 (Pubitemid 32844785)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.17
, pp. 3733-3739
-
-
De Jongh, F.E.1
Verweij, J.2
Loos, W.J.3
De Wit, R.4
De Jonge, M.J.A.5
Planting, A.S.T.6
Nooter, K.7
Stoter, G.8
Sparreboom, A.9
-
29
-
-
14144253314
-
Influence of sex on toxicity and treatment outcome in small-cell lung cancer
-
DOI 10.1200/JCO.2005.03.171
-
S Singh W Parulekar N Murray R Feld WK Evans D Tu FA Shepherd 2005 Influence of sex on toxicity and treatment outcome in small-cell lung cancer J Clin Oncol 23 850 856 15681530 10.1200/JCO.2005.03.171 (Pubitemid 46224185)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.4
, pp. 850-856
-
-
Singh, S.1
Parulekar, W.2
Murray, N.3
Feld, R.4
Evans, W.K.5
Tu, D.6
Shepherd, F.A.7
-
30
-
-
79952680409
-
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1
-
Edlund P, Ahlgren J, Bjerre K, Andersson M, Bergh J, Mouridsen H, Holmberg S B, Bengtsson N O, Jakobsen E, Moller S, Lindman H, and Blomqvist C Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1. Acta Oncol 50:329-337
-
Acta Oncol
, vol.50
, pp. 329-337
-
-
Edlund, P.1
Ahlgren, J.2
Bjerre, K.3
Andersson, M.4
Bergh, J.5
Mouridsen, H.6
Holmberg, S.B.7
Bengtsson, N.O.8
Jakobsen, E.9
Moller, S.10
Lindman, H.11
Blomqvist, C.12
-
31
-
-
0037445132
-
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
-
DOI 10.1200/JCO.2003.02.063
-
IC Henderson DA Berry GD Demetri CT Cirrincione LJ Goldstein S Martino JN Ingle MR Cooper DF Hayes KH Tkaczuk G Fleming JF Holland DB Duggan JT Carpenter E Frei 3rd RL Schilsky WC Wood HB Muss L Norton 2003 Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976 983 12637460 10.1200/JCO.2003.02.063 1:CAS:528:DC%2BD2cXpsVGqs7c%3D (Pubitemid 46594124)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.6
, pp. 976-983
-
-
Henderson, I.C.1
Berry, D.A.2
Demetri, G.D.3
Cirrincione, C.T.4
Goldstein, L.J.5
Martino, S.6
Ingle, J.N.7
Cooper, M.R.8
Hayes, D.F.9
Tkaczuk, K.H.10
Fleming, G.11
Holland, J.F.12
Duggan, D.B.13
Carpenter, J.T.14
Frei III, E.15
Schilsky, R.L.16
Wood, W.C.17
Muss, H.B.18
Norton, L.19
-
32
-
-
0037132703
-
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001
-
SD Baker J Verweij EK Rowinsky RC Donehower JH Schellens LB Grochow A Sparreboom 2002 Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001 J Natl Cancer Inst 94 1883 1888 12488482 10.1093/jnci/94.24.1883 1:CAS:528:DC%2BD3sXlsFyisA%3D%3D (Pubitemid 36104633)
-
(2002)
Journal of the National Cancer Institute
, vol.94
, Issue.24
, pp. 1883-1888
-
-
Baker, S.D.1
Verweij, J.2
Rowinsky, E.K.3
Donehower, R.C.4
Schellens, J.H.M.5
Grochow, L.B.6
Sparreboom, A.7
-
33
-
-
33645735425
-
Developing a new framework for dose calculation
-
DOI 10.1200/JCO.2005.05.1607
-
H Gurney 2006 Developing a new framework for dose calculation J Clin Oncol 24 1489 1490 16574997 10.1200/JCO.2005.05.1607 (Pubitemid 46638768)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.10
, pp. 1489-1490
-
-
Gurney, H.1
-
34
-
-
0031860380
-
Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation
-
HP Gurney S Ackland V Gebski G Farrell 1998 Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation J Clin Oncol 16 2299 2304 9667243 1:CAS:528:DyaK1cXks1GntLw%3D (Pubitemid 28309020)
-
(1998)
Journal of Clinical Oncology
, vol.16
, Issue.7
, pp. 2299-2304
-
-
Gurney, H.P.1
Ackland, S.2
Gebski, V.3
Farrell, G.4
-
35
-
-
0029958848
-
Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients
-
M Sandstrom A Freijs R Larsson P Nygren ML Fjallskog J Bergh MO Karlsson 1996 Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients J Clin Oncol 14 1581 1588 8622075 1:STN:280:DyaK283gvVygtA%3D%3D (Pubitemid 26134217)
-
(1996)
Journal of Clinical Oncology
, vol.14
, Issue.5
, pp. 1581-1588
-
-
Sandstrom, M.1
Freijs, A.2
Larsson, R.3
Nygren, P.4
Fjallskog, M.-L.5
Bergh, J.6
Karlsson, M.O.7
-
36
-
-
33646517096
-
Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients
-
16465545 10.1007/s00280-005-0140-2 1:STN:280:DC%2BD283js1Krtg%3D%3D
-
M Sandstrom H Lindman P Nygren M Johansson J Bergh MO Karlsson 2006 Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients Cancer Chemother Pharmacol 58 143 156 16465545 10.1007/s00280-005-0140-2 1:STN:280:DC%2BD283js1Krtg%3D%3D
-
(2006)
Cancer Chemother Pharmacol
, vol.58
, pp. 143-156
-
-
Sandstrom, M.1
Lindman, H.2
Nygren, P.3
Johansson, M.4
Bergh, J.5
Karlsson, M.O.6
-
37
-
-
1542753592
-
Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices
-
DOI 10.1200/JCO.2003.05.002
-
GH Lyman DC Dale J Crawford 2003 Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices J Clin Oncol 21 4524 4531 14673039 10.1200/JCO.2003.05.002 (Pubitemid 46594022)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.24
, pp. 4524-4531
-
-
Lyman, G.H.1
Dale, D.C.2
Crawford, J.3
-
38
-
-
10344230139
-
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study
-
DOI 10.1200/JCO.2004.03.213
-
GH Lyman DC Dale J Friedberg J Crawford RI Fisher 2004 Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study J Clin Oncol 22 4302 4311 15381684 10.1200/JCO.2004.03.213 1:CAS:528:DC%2BD2cXhtVKju7fO (Pubitemid 41185151)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.21
, pp. 4302-4311
-
-
Lyman, G.H.1
Dale, D.C.2
Friedberg, J.3
Crawford, J.4
Fisher, R.I.5
-
39
-
-
0242287522
-
Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients
-
DOI 10.1038/sj.bjc.6601279
-
RC Leonard D Miles R Thomas F Nussey 2003 Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients Br J Cancer 89 2062 2068 14647139 10.1038/sj.bjc.6601279 1:CAS:528:DC%2BD3sXpt1CitL0%3D (Pubitemid 38030904)
-
(2003)
British Journal of Cancer
, vol.89
, Issue.11
, pp. 2062-2068
-
-
Leonard, R.C.F.1
Miles, D.2
Thomas, R.3
Nussey, F.4
|